These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 25911108)

  • 1. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
    Hartung DM; Bourdette DN; Ahmed SM; Whitham RH
    Neurology; 2015 May; 84(21):2185-92. PubMed ID: 25911108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
    Kim Y; Krause TM; Blum P; Freeman L
    Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of generic glatiramer acetate on spending and use of drugs for multiple sclerosis.
    Hartung DM; Johnston KA; Geddes J; Bourdette DN
    Neurology; 2020 Mar; 94(13):e1407-e1414. PubMed ID: 31941796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The fiscal consequences of public health investments in disease-modifying therapies for the treatment of multiple sclerosis in Sweden.
    Kotsopoulos N; Connolly MP; Dort T; Kavaliunas A
    J Med Econ; 2020 Aug; 23(8):831-837. PubMed ID: 32400258
    [No Abstract]   [Full Text] [Related]  

  • 5. Trends in the use of disease-modifying therapies among reproductive-aged women with multiple sclerosis in the United States from 2010 to 2019.
    Duchesneau ED; Kinlaw AC; Jonsson Funk M; Pate V; Lund JL
    Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):481-487. PubMed ID: 35088492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in Prices, Market Share, and Spending on Self-administered Disease-Modifying Therapies for Multiple Sclerosis in Medicare Part D.
    San-Juan-Rodriguez A; Good CB; Heyman RA; Parekh N; Shrank WH; Hernandez I
    JAMA Neurol; 2019 Nov; 76(11):1386-1390. PubMed ID: 31449293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.
    Setayeshgar S; Kingwell E; Zhu F; Zhang X; Zhang T; Marrie RA; Carruthers R; Tremlett H
    Mult Scler Relat Disord; 2018 Oct; 25():57-60. PubMed ID: 30036855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System database.
    Stamatellos VP; Siafis S; Papazisis G
    Br J Clin Pharmacol; 2021 Dec; 87(12):4769-4779. PubMed ID: 33998034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA.
    Hartung DM
    Curr Neurol Neurosci Rep; 2021 May; 21(7):28. PubMed ID: 33948740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
    Wijnands JMA; Zhu F; Kingwell E; Fisk JD; Evans C; Marrie RA; Zhao Y; Tremlett H
    J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1050-1056. PubMed ID: 29602795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' preferences and willingness-to-pay for disease-modifying therapies.
    Frost N; Freeman J; Brixner D; Mort J; Clem J; Ngorsuraches S
    Mult Scler Relat Disord; 2019 Oct; 35():55-60. PubMed ID: 31323483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use and safety of disease-modifying therapy in pregnant women with multiple sclerosis.
    MacDonald SC; McElrath TF; Hernández-Díaz S
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):556-560. PubMed ID: 30834654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.
    Krysko KM; Graves JS; Rensel M; Weinstock-Guttman B; Rutatangwa A; Aaen G; Belman A; Benson L; Chitnis T; Gorman M; Goyal MS; Harris Y; Krupp L; Lotze T; Mar S; Moodley M; Ness J; Rodriguez M; Rose J; Schreiner T; Tillema JM; Waltz M; Casper TC; Waubant E;
    Ann Neurol; 2020 Jul; 88(1):42-55. PubMed ID: 32267005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New treatments and strategy in multiple sclerosis].
    Guéguen A; Gout O
    Rev Prat; 2016 Jan; 66(1):44-50. PubMed ID: 30512399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States.
    Nicholas J; Halpern R; Ziehn M; Peterson-Brandt J; Leszko M; Deshpande C
    J Med Econ; 2020 Aug; 23(8):885-893. PubMed ID: 32338098
    [No Abstract]   [Full Text] [Related]  

  • 16. Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020.
    Henderson M; Horton DB; Bhise V; Pal G; Bushnell G; Dave CV
    JAMA Neurol; 2023 Aug; 80(8):860-867. PubMed ID: 37428482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis.
    Li P; Ladage VP; Berger J; Chahin S; Jhaveri M; Geremakis C; Doshi JA
    Value Health; 2020 Mar; 23(3):328-334. PubMed ID: 32197728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022.
    Zhao T; Taylor BV; Campbell JA; Palmer AJ
    Mult Scler; 2024 Jan; 30(1):80-88. PubMed ID: 38116594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Closing the Part D Coverage Gap and Out-of-Pocket Costs for Multiple Sclerosis Drugs.
    Hartung DM; Johnston KA; Bourdette DN; Chen R; Tseng CW
    Neurol Clin Pract; 2021 Aug; 11(4):298-303. PubMed ID: 34484929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescription trends of disease-modifying treatments for multiple sclerosis in Iran over the past 30 years.
    Ghadiri F; Sahraian MA; Baghbanian SM; Ashtari F; Razazian N; Majdinasab N; Poursadeghfard M; Hatamian H; Harirchian MH; Beladimoghadam N; Azimi A; Sharifipour E; Hosseini S; Bayati A; Kamali H; Hosseni Nejad Mir N; Faraji F; Mozhdehipanah H; Modara F; Navardi S; Heidari H; Ayoubi S; Naser Moghadasi A; Eskandarieh S
    Mult Scler Relat Disord; 2022 May; 61():103777. PubMed ID: 35390594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.